Hansa Medical mourns death of CEO
pharmafile | November 13, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Hansa Medical, pharma
Swedish biopharma firm Hansa Medical broke tragic and unexpected news in November when it announced the death of its CEO Göran Arvidson following his short time with the company.
Arvidson boasted a long and dynamic career in the industry, having held senior roles at Pharmacia and Swedish Orphan Biovitrum in the past. He joined Hansa in January 2015 as Chief Financial Officer, quickly moving up to become acting CEO before permanently taking on the role on 30 April in the same year.
“It is with great regret that we announce the passing of Göran Arvidson which is both deeply tragic and completely unexpected,” said Ulf Wiinberg, Chairman of Hansa Medical. “Göran Arvidson has left us suddenly and unexpectedly. Our thoughts go to Göran’s family and to those closest to him.”
He continued: “With his solid experience from the pharmaceutical industry and through his strong and genuine commitment, Göran has been an outstanding strong and skilled leader for Hansa Medical, which, in our view, has become a very promising pharmaceutical company. We are very grateful for the time that we had Göran at the helm.”
Wiinberg himself will step in to fill the role in the interim until the company can find a permanent replacement. He had previously served as CEO of Lundbeck until 2004, when he was ousted from the role for breaking the company’s code of conduct regarding share ownership. Meanwhile, board member Birgit Stattin Norinder will take over as chairman of the board until further notice.
Image credit: Hansa Medical
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …
